Endometrial Cancer      

FOI REFERENCE: 24512   FOI DATE: 11^th November 2024      

Q1.  Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?  Yes

Q2.  How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments: 

• Dostarlimab (Jemperli) 1 Patient
• Dostarlimab (Jemperli) AND Chemotherapy 0 Patients
• Hormone therapy (Progesterone or Letrozole) 0 Patients
• Pembrolizumab (Keytruda) monotherapy 1 Patient
• Lenvatinib + Pembrolizumab (Lenvima +Keytruda)  8 Patients
• Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)  7 Patients
• Any other SACT  Denosumab 1 Patient
• Any other Chemotherapy n/a

Q3.  In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy? 0 Patients

Q4.  In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments: 

• Dostarlimab (Jemperli) AND Chemotherapy 0 Patients

• Hormone therapy (Progesterone or Letrozole) 0 Patients
• Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) 7 Patients
• Any other SACT Not Applicable
• Any other chemotherapy Not Applicable

TO BE AWARE ALTHOUGH MOSIAQ (Oncology Management System) HOLDS TREATMENT GIVEN IT MAY NOT BE NECCESARILY THE FIRST TREATMENT PATHWAY THIS INFO DOESN’T EXIST IN MOSAIQ

Q5.  Does your trust participate in any clinical trials for the treatment of endometrial cancer?  If so, can you please provide the name of each trial and the number of patients taking part. Worcestershire Acute Hospitals NHS Trust are not currently enrolled in any endometrial cancer trials.